Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of GNR-044 vs Xolair in Healthy Volunteers
NCT04601389Phase 1Completed
- Sponsor
- Generium
- Start
- Apr 2017
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of omalizumab in asthma (2 arms), sponsored by Generium. Primary endpoints: Time to Maximum Concentration up to 2016 hours, Maximum Concentration up to 2016 hours and 9 more. Started Apr 2017; status: completed.
02
Drugs
omalizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04601389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04601389.